Abstract
Long QT interval is an important finding that is often missed by electrocardiogram interpreters. Long QT syndrome (inherited and acquired) is a potentially lethal cardiac channelopathy that is frequently mistaken for epilepsy. We present a case of long QT syndrome with multiple cardiac arrests presenting as syncope and seizures. The long QTc interval was aggravated by hypomagnesaemia and drugs, including clarithromycin and levofloxacin. Multiple drugs can cause prolongation of the QT interval, and all physicians should bear this in mind when prescribing these drugs.
Keywords: causes, diagnosis and management, ECG, long QT interval, torsade de pointes
CLINICAL PRESENTATION
A 44-year-old man presented to the emergency department with a one-week history of cough, fever, non-vertiginous giddiness and generalised weakness. He had a history of renal failure requiring renal replacement therapy, myelodysplastic syndrome and gout. One day prior to the presentation, the patient had an episode of unwitnessed seizure while resting at home. He denied any tongue-bite injury, involuntary micturition or defecation. His last dialysis was uneventful. On examination, he was found to be haemodynamically stable. On auscultation of his chest, a few right basal crepitations were heard. No focal neurological deficit was observed. The patient was admitted for suspected chest infection.
The initial laboratory evaluation showed the following: white blood cell count of 2.73 × 109/L with neutrophils at 61%; C-reactive protein 44 mg/L (reference range < 10); serum potassium 4.4 mmol/L (reference range 3.5–5.0); calcium 2.02 mmol/L (reference range 2.15–2.55); phosphate 1.14 mmol/L (reference range 0.85–1.45); and magnesium 0.55 mmol/L (reference range 0.75–1.07). Chest radiography showed small bilateral pleural effusion with right lower lobe atelectasis, raising a suspicion of underlying pneumonia.
In the ward, the patient was febrile, although his blood cultures did not show microbial growth, he underwent treatment for chest infection with initially oral clarithromycin (one dose), which was subsequently changed to oral levofloxacin. His electrolyte imbalance was corrected. During his inpatient hospital stay, the patient developed two episodes of seizure-like events at rest, for which he underwent electroencephalography and magnetic resonance imaging of the brain, which were both normal. An electrocardiogram (ECG) was done on arrival at the emergency department.
What does the ECG in Fig. 1 show?
Fig. 1.

Initial ECG shows sinus rhythm with deep T wave inversion and prolongation of the QTc interval.
ECG INTERPRETATION
Initial ECG (Fig. 1) shows sinus rhythm, with a heart rate of 62 beats per minute. There are deep T wave inversions in the chest leads, with prolonged corrected QT interval at 700 msec. The long QT interval was presumed to be due to a combination of clarithromycin use, hypomagnesaemia and hypocalcaemia. Clarithromycin was stopped after only one dose and electrolytes were replaced. The patient was subsequently discharged well. The primary team had noticed the long QT interval and planned for 24-hour Holter monitoring, transthoracic echocardiography and subsequent cardiology review in the outpatient clinic.
CLINICAL COURSE
On the fifth day after discharge, the patient again presented to the emergency department for two brief episodes of sudden loss of consciousness, with tonic-clonic seizures and up rolling of eyes. Both episodes, which occurred after the completion of dialysis, were witnessed by the patient’s wife. While waiting in the emergency department, he developed another tonic-clonic seizure. A second ECG (Fig. 2) was performed at this presentation. The ECG rhythm shows polymorphic ventricular tachycardia, with phasic variation in polarity and amplitude of QRS complexes suggestive of torsade de pointes (TdP), which subsequently disintegrated into ventricular fibrillation. A direct current shock of 150 joules converted the rhythm to sinus.
Fig. 2.

ECG shows polymorphic ventricular tachycardia (torsade de pointes), which disintegrated into ventricular fibrillation, and subsequent successful electrical cardioversion.
Initial electrolyte screening showed the presence of hypomagnesaemia and hypocalcaemia. The electrolytes were replaced and the patient was subsequently started on beta-blocker therapy. Transthoracic echocardiogram showed a structurally normal heart with normal left ventricular systolic function. An automatic implantable cardioverter defibrillator (AICD) was implanted before his discharge. Although genetic evaluation was not conducted, it was likely that the patient had inherited long QT syndrome (LQTS) (type III variant), based on T wave morphology in the ECG. ECG after implantation of AICD (Fig. 3) shows pacemaker rhythm (atrial-paced, ventricular-sensed). Although the QTc was still prolonged at 600 msec, it was shorter than that shown in the initial ECG (Fig 1).
Fig. 3.

Post-automatic implantable cardioverter defibrillator ECG shows pacemaker rhythm and prolonged QTc interval (600 msec).
DISCUSSION
LQTS due to inherited and acquired cardiac channelopathies can present with life-threatening ventricular arrhythmias in a structurally normal heart. In this case, the patient presented with symptoms of chest infection, with multiple episodes of sudden unconsciousness and seizures due to prolonged QT interval causing sustained TdP and ventricular arrhythmias. Prolongation of QT interval has many causes, the common ones being drugs and electrolyte disturbances. However, in this case, patient’s baseline ECG prior to medication (clarithromycin and levofloxacin) showed a markedly prolonged QTc interval of 700 msec. Following correction of electrolyte abnormalities and discontinuation of the culprit medications, the patient developed two episodes of seizures due to ventricular arrhythmias, which points to a high likelihood of congenital LQTS. Hypomagnesaemia, hypocalcaemia and medications most likely unmasked the underlying condition. The patient was started on beta-blocker therapy at a maximally tolerated dose. In view of the multiple episodes of arrhythmias causing syncope, seizures and cardiac arrest, an AICD was implanted for secondary prevention.
QT interval represents the duration of ventricular electrical systole, which includes ventricular activation and recovery. It is measured from the beginning of the QRS complex to the end of the T wave. The duration of repolarisation (JT interval) is dependent on heart rate; QT interval is shorter with tachycardia and longer with bradycardia. Therefore, QT interval is always corrected for the given heart rate (QTc).
There are many formulae for correction of the QT interval, including Bazett’s,(1) Fridericia’s,(2) Framingham’s,(3) normograms and linear regression formulae. In previous studies, linear regression, exponential, cubic root (Fridericia) formulae have been found to be more accurate than the Bazett’s method; however, none of these are ideal even though their inaccuracy rate is in the range of 4–5 msec, which is negligible.(4) The most commonly used formula, the modified Bazett’s formula(1) is as follows:

The normal range of corrected QTc is below 0.44 sec in males and 0.46 sec in females; values > 0.45 sec in males and > 0.47 sec in females are considered as prolonged.(5)
Long QT syndrome
LQTS may be inherited or acquired, with the latter being more common. It is characterised by prolonged QT interval on ECG, which predisposes to malignant ventricular tachyarrhythmia, TdP, ventricular fibrillation and sudden death. The presentation can be variable, from asymptomatic to symptoms of syncope, seizures and palpitations to sudden death. Inherited LQTS is the prototype of ‘primary cardiac arrhythmias’ or ‘cardiac ion channelopathies’, while acquired LQTS is often a result of electrolyte disturbances and drug-induced QT prolongation.
Congenital LQTS
In 1957, Jervell and Lange-Nielsen(6) were the first to describe a Norwegian family in which four out of ten of the children were deaf and had recurrent syncope during exercise or as a result of increased emotion. Three had died suddenly at ages four, five and nine years old. Marked QT prolongation was noted on the ECG of the children. Inheritance appeared to be autosomal recessive and associated with sensorineural deafness.(6) A similar clinical syndrome of sudden death during exercise and increased emotion, with normal hearing and autosomal dominant inheritance, was described by Romano et al in 1963 and Ward in 1964.(7,8) The two different phenotypes of congenital LQTS were subsequently named Jervell and Lange-Nielsen syndrome for the autosomal recessive variant and Romano-Ward syndrome for the autosomal dominant variant without sensorineural deafness.
There are at least 13 LQTS genotypes (LQT 1-13) with over 200 mutations in various genes.(9) LQTS 1, 2 and 3 are the most common, making up 80%–90% of the total cases of inherited LQTS.(9,10) The three genes and related ionic currents responsible are LQTS1 (KCN 1), LQTS2 (KCNH2) and LQTS3 (SNC5A).(9,10) Genotype is a modulator of LQTS phenotype; gene-specific differences have been described in terms of the morphology of the ST-T wave complex, triggers for cardiac events, and risk of cardiac events.(11) Patients with LQTS1 experience the majority of events during exercise or heightened emotions, those with LQTS2 during heightened emotion and those with LQTS3 usually during sleep and less with exercise.(10)
Although the most important expected finding in these cases is the presence of prolonged QT interval, up to 10%–35% of patients with LQTS may present with a normal QT interval,(12) which makes it difficult to screen such patients. The T wave morphology may give some clue regarding the type of LQTS. LQT 1 usually has an infantile ST-T wave pattern, with broad pronounced T wave, LQT 2 commonly has low-amplitude bifid T wave, and LQT 3 has late-appearing T wave with steep downslope.(13)
Depending on the genotypes, QTc values > 500 msec confer a five- to eightfold increased risk of experiencing at least one cardiac event up to the age of 40 years.(11) Highest-risk patients for cardiac events before 40 years of age comprise females with LQTS2, and males with LQTS3 and QTc > 500 msec.(11) These two genotypes also have a suboptimal response to beta-blocker therapy, unlike LQTS1.(14)
Management of patients with inherited LQTS include: (a) avoidance of triggers such as exercise, competitive sports (ACC/AHA class I indication) and drugs that prolong QT interval; (b) prevention of potassium loss and prompt replacement of any loss; and (c) use of appropriate beta-blocker therapy. Beta-blockers are the mainstay of therapy, with propranolol (2–4 mg/kg/day), metoprolol (2–4 mg/kg/day) and nadolol (1–2.5 mg/kg/day) being most commonly administered. The ACC/AHA/ESC guidelines on prevention of sudden cardiac death indicate that ICD is a class I indication in all patients with LQTS with prior cardiac arrest, and a class IIb indication in the presence of QTc > 500 msec LQTS 2 and LQTS 3 subtypes, which are less responsive to conventional beta-blocker therapy.(15)
Acquired LQTS
The main predisposing factors for acquired LQTS are mediations and electrolyte imbalances, commonly hypomagnesaemia, hypokalaemia or hypocalcaemia.(16) Additionally conditions like extreme bradycardia due to atrioventricular nodal disease or sick sinus syndrome, hypothyroidism, hypothermia and anorexia nervosa can predispose patients to prolonged QT interval. It must be kept in mind that drugs are the most common causes of prolonged QT interval. In the past, several drugs have been withdrawn or received black box warning due to their potential to cause QT interval prolongation that may lead to fatal ventricular arrhythmias and sudden cardiac deaths.(16,17)
Torsade de pointes
TdP is a type of polymorphic ventricular tachycardia associated with prolonged QT interval or increased U wave amplitude that responds to increases in the heart rate.(18,19) To be considered TdP, the axis of the QRS complex must change in direction and show variation in polarity and amplitude.(20) Tachycardia is usually at the rate of 200–250 beats per minute. Although not pathognomonic, in most cases, it is preceded by a sequence of a long RR interval of the dominant cycle followed a short extrasystolic interval with premature depolarisation interrupting the T wave.(21)
Some of commonly prescribed drugs that can result in prolonged QT interval include:(16,17,22-25) (a) antiarrhythmic agents: procainamide, quinidine, amiodarone, flecainide, propofenone, disopyramide, dronedarone, sotalol, dofetilide, ibutilide; (b) antihistamines: terfenadine, astimazole; (c) antipsychotics: quetiapine, haloperidol, clozapine; (d) tri- and tetra-cyclic antidepressants: imipramine, doxepin; (e) selective serotonin reuptake inhibitors: citalopram, fluoxetine; (f) antimicrobial agents: fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, ofloxacin), macrolides (erythromycin, clarithromycin, azithromycin), antifungal agents (ketokonazole, voriconazole); and (g) antimalarial agents: quinine, mefloquine, chloroquine.
Currently, more than 50 commonly prescribed medications cause QT prolongation and/or have been associated with TdP or sudden death. Management of acquired LQTS involves the correction of electrolyte imbalances, avoidance of medications that can cause prolong QT and TdP, ECG monitoring and prompt treatment of arrhyrhmias. In patients with TdP, prompt electric defibrillation should be administered in haemodynamically unstable patients. Intravenous magnesium sulphate is highly effective in the treatment and prevention of long QT-related arrhythmias.(26,27) Other therapies include overdrive pacing and the use of isoproterenol.(26)
In conclusion, the finding of long QT interval is important in clinical practice. However, this is often missed when interpreting ECG. Inherited and acquired LQTS is a potentially lethal cardiac channelopathy that is frequently mistaken for epilepsy. As many drugs can cause prolongation of the QT interval, physicians should be cognizant of this fact when prescribing such drugs to at-risk patients.
REFERENCES
- 1.Bazett HC. An analysis of time relations of the electrocardiogram. Heart. 1920;7:353–70. [Google Scholar]
- 2.Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease 1920. Ann Noninvasive Electrocardiol. 2003;8:343–51. doi: 10.1046/j.1542-474X.2003.08413.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Am J Cardiol. 1992;70:797–801. doi: 10.1016/0002-9149(92)90562-d. [DOI] [PubMed] [Google Scholar]
- 4.Malik M. Problems of heart rate correction in assessment of drug-induced QT prolongation interval. J Cardiovasc Electrophysiol. 2001;12:411–20. doi: 10.1046/j.1540-8167.2001.00411.x. [DOI] [PubMed] [Google Scholar]
- 5.Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:23B–25B. doi: 10.1016/0002-9149(93)90036-c. [DOI] [PubMed] [Google Scholar]
- 6.Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J. 1957;54:59–68. doi: 10.1016/0002-8703(57)90079-0. [DOI] [PubMed] [Google Scholar]
- 7.Romano C, Gemmer G, Pongiglione R. [Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation (presentation of 1st case in italian pediatric literature)] Clin Pediatr. 1963;45:656–83. Italian. [PubMed] [Google Scholar]
- 8.Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc. 1964;54:103–106. [PubMed] [Google Scholar]
- 9.Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-qt syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178–85. doi: 10.1161/01.cir.102.10.1178. [DOI] [PubMed] [Google Scholar]
- 10.Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95. doi: 10.1161/01.cir.103.1.89. [DOI] [PubMed] [Google Scholar]
- 11.Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–74. doi: 10.1056/NEJMoa022147. [DOI] [PubMed] [Google Scholar]
- 12.Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975–80. doi: 10.1001/jama.294.23.2975. [DOI] [PubMed] [Google Scholar]
- 13.Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000;102:2849–55. doi: 10.1161/01.cir.102.23.2849. [DOI] [PubMed] [Google Scholar]
- 14.Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341–4. doi: 10.1001/jama.292.11.1341. [DOI] [PubMed] [Google Scholar]
- 15.Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task force and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol. 2006;48:e247–346. doi: 10.1016/j.jacc.2006.07.010. [DOI] [PubMed] [Google Scholar]
- 16.Al-Khatib SM, Allen La Pionte N, Kramer JM, Califf RM. What clinicians should know about the QT interval? JAMA. 2003;289:2120–7. doi: 10.1001/jama.289.16.2120. [DOI] [PubMed] [Google Scholar]
- 17.Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–72. doi: 10.1136/heart.89.11.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Coumel P, Leclercq JF, Lucet V. Possible mechanisms of the arrhythmias in long QT syndrome. Eur Heart J. 1985;6(Suppl D):115–29. doi: 10.1093/eurheartj/6.suppl_d.115. [DOI] [PubMed] [Google Scholar]
- 19.Nguyen PT, Scheinman MM, Sege J. Polymorphous ventricular tachycardia: clinical characterization, therapy and the QT interval. Circulation. 1986;74:340–9. doi: 10.1161/01.cir.74.2.340. [DOI] [PubMed] [Google Scholar]
- 20.Sclarovsky S, Strasberg B, Lewin RF, Agmon J. Polymorphous ventricular tachycardia: clinical features and treatment. Am J Cardiol. 1979;44:339–44. doi: 10.1016/0002-9149(79)90326-6. [DOI] [PubMed] [Google Scholar]
- 21.Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806–17. doi: 10.1016/s0735-1097(83)80226-5. [DOI] [PubMed] [Google Scholar]
- 22.Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Supplements. 2001;3(suppl K):S70–S80. [Google Scholar]
- 23.Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107:85–95. doi: 10.1034/j.1600-0447.2003.02078.x. [DOI] [PubMed] [Google Scholar]
- 24.Haddad PM, Anderson IM. Anti-psychotic related QTc prolongation, torsades de pointes and sudden death. Drugs. 2002;62:1649–71. doi: 10.2165/00003495-200262110-00006. [DOI] [PubMed] [Google Scholar]
- 25.Woosley RL. Drugs that prolong the QT interval and/or induce torsades de pointes. Revised November 18, 2014 [online] [Accessed November 30 2014]. Available at: www.QTdrugs.org .
- 26.Khan IA. Long QT syndrome: diagnosis and management. Am Heart J. 2002;143:7–14. doi: 10.1067/mhj.2002.120295. [DOI] [PubMed] [Google Scholar]
- 27.Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392–7. doi: 10.1161/01.cir.77.2.392. [DOI] [PubMed] [Google Scholar]
